Content available at: <https://www.ipinnovative.com/open-access-journals>

International Journal of Pharmaceutical Chemistry and Analysis

Journal homepage: <https://www.ijpca.org/>

Review Article

A review: Pathophysiology, diagnosis and management of multiple sclerosis

Sourabh D Jain^{1,*}, Pawandeep Shukla², Ankit Agrawal³, Shikha Sharma¹¹Dept. of Pharmaceutical Chemistry, Chameli Devi Institute of Pharmacy, Indore, Madhya Pradesh, India²Dept of Pharmacognosy, Chameli Devi Institute of Pharmacy, Indore, Madhya Pradesh, India³Dept. of Pharmaceutics, Chameli Devi Institute of Pharmacy, Indore, Madhya Pradesh, India

ARTICLE INFO

Article history:

Received 18-03-2021

Accepted 22-03-2021

Available online 04-05-2021

Keywords:

Multiple Sclerosis (MS)

Symptomatic

Acute attack and Disease modifying

ABSTRACT

Multiple Sclerosis (MS) is common, non-traumatic disability disease which affects young peoples. The incidence of multiple sclerosis is increasing worldwide with socioeconomic impact of the disease. Multiple sclerosis affect about more than 2 million people and currently it is incurable. The ratio of effect of MS in women and men is 2:1 respectively. Approx 250, 000- to 350,000 people are diagnosed with MS in the USA and about 10,000 new cases diagnosed each year. The epidemiology of Multiple sclerosis indicates that low serum levels of vitamin D, smoking, obesity and infection etc. are likely to play a role in disease development. In case of treatment of MS, it is divided three phases include: symptomatic, acute attack and disease modifying methods. In case of symptomatic around helping to maintain a patient's quality of life. Treatment of acute attack is centered on the treatment of exacerbations that affects a patient's functional ability. In disease modifying treatment focuses on the long term management of the disease with the goal to reduce relapse rates, lessen severity and to slow the progression of disability.

© This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

1. Introduction

Multiple sclerosis is an auto immune disorder that affects central nervous system and it leads to severe physical and cognitive incapacitation as well as neurological problems in young adults. However MS is somewhat influenced by B cells through a variety of mechanisms, including ectopic lymphoid follicles in the CNS, present antigen, production of cytokine and production of antibodies. Multiple sclerosis is considered the most common cause of neurological disability while inflammatory lesions associated with MS may affect a large range of systems and cause a variety of neurological symptoms.^{1,2}

Multiple sclerosis presents between 20 and 40 years of age and the women are more susceptible than men. The exact pathophysiology of multiple sclerosis is not known but it seems to be autoimmune in nature.³

* Corresponding author.

E-mail address: sourabhjain072@gmail.com (S. D. Jain).2. Types of Multiple Sclerosis⁴⁻⁶

Multiple sclerosis is extremely variable with symptoms that may appear, disappear or sometimes worsen over time and it is possible and to classify people according to the course of their disease.

1. Relapsing remitting multiple sclerosis
2. Secondary progressive multiple sclerosis
3. Primary progressive multiple sclerosis
4. Progressive relapsing multiple sclerosis

The treatment strategy for multiple sclerosis is broadly based on disease – modifying drugs such as interferon – β and glatiramer acetate. Multifocal zones of inflammation due to T- lymphocyte and macrophage infiltrations and are the primary causes of myelin sheath destruction that result in the formation of CNS plaques.

3. Pathogenesis of Multiple Sclerosis

Multiple sclerosis shows a variety of neurological symptoms that spread in different parts of the CNS. It may occur alone or combined. These symptoms are quite vary from patient to patient but it may involve sensory disturbance, dysfunction of bladder, vision loss limb weakness, fatigue and troubles in bowel. Typically the disease starts with the sudden onset of neurological deficits.^{7,8}

Only small percentage of patients feel a gradually progressive clinical course from the onset of the disease such as clinical course refers to the principal progressive form of MS. Therefore the steady progression of symptoms associated with primary progressive MS leads to disability from the beginning.^{9,10}

Fig. 1: Pathogenesis of multiple sclerosis with immune cell and their cytokines

4. Diagnosis Approaches

Basically the diagnosis of multiple sclerosis is based on the demonstration of MS- typical CNS lesions disseminated in space and time which based upon clinical findings alone or it a combination of clinical and MRI approach. It's also being diagnosed with the demonstration of neurological sign and symptoms.^{10–12}

Table 1: More common symptoms of Multiple Sclerosis (MS)

Primary symptoms	More common symptoms	Dizziness, emotional impairment, vision problems and walking difficulty
	Less common symptoms	Hearing, Headache, breathing and Speech problems and swallowing etc.
Secondary symptoms	Urinary tract infections	
Tertiary symptoms	Depression, Psychological and social complications.	

Nowadays the diagnosis of MS based on the result of MRI examination. For MRI examination a contrast agent like gadolinium used to highlight active plaques, MRI allows detecting plaques that are ongoing to destruction of the BBB. Apart of this diagnosis tools various potentials test including visual, brain stem auditory and somatosensory, these furnished the information about demyelization in the optic nerve and CNS. In addition, CSF analysis for myelin basic protein and immunoglobulin gamma (Ig G) determination and blood sample analysis for detection of vitamin deficiencies may be helpful.^{13,14}

5. Management of Multiple Sclerosis

In previous studies we know that there is no current treatment of multiple sclerosis but Therapeutic management may be useful. Therapeutic management can be dividing into relapse treatment, Symptomatic treatment and disease- modifying treatment. In relapse treatment the Methylprednisolone at dose of 1 g/day or 500 mg/day for 305 days with or without oral tapering. Alternatively the treatment continues with equal dose via oral administration.

In disease- modifying treatment, potentially ameliorate the disease course are studied and in case the clinical course is dominated by relapses as for the clinically isolated syndrome RRMS and occasionally SPMS.

The basic therapeutics deals with immunomodulators like IFN β and glatiramer acetate are used as first line therapeutics which help in reducing the relapse rate and do not cause any severe side effect. Teriflunomide and fingolimod are also used as basic therapeutics.

Basic therapeutics Apart from above treatment some therapies like Escalation therapy and Symptomatic treatment etc. are also available which more beneficial in the treatment of multiple sclerosis.^{15,16}

6. Conclusion

The actual cause of multiple sclerosis is unknown. Various factors influences play an important role in the pathogenesis of this disease. Several drugs having therapeutic effect anti inflammatory drugs, immunomodulators in multiple sclerosis have been studied. In present research, current treatment is not available but beside drug therapies like ADSCs which gives the idea of cell transplantation. This idea may provide a novel strategy for the treatment of neurological disease.

7. Source of Funding

None.

8. Conflict of Interest

The authors declare that there is no conflict of interest.

References

1. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. *J Neurol Sci.* 2003;206(2):165–71. doi:10.1016/s0022-510x(02)00069-2.
2. Jersild T. Penicillin in Scarlet Fever. *BMJ.* 1948;1:318. doi:10.1136/bmj.1.4545.318-c.
3. Trapp BD, Nave KA. Multiple Sclerosis: An Immune or Neurodegenerative Disorder? *Annu Rev Neurosci.* 2008;31(1):247–69. doi:10.1146/annurev.neuro.30.051606.094313.
4. Alonso A, Hermain MA. Temporal trends in the incidence of multiple sclerosis: a systemic review. *Neurology.* 2000;71:129–35.
5. Gandhi R, Laroni A, Weiner HL. Role of the innate immune system in the pathogenesis of multiple sclerosis. *J Neuroimmunol.* 2010;221(1-2):7–14. doi:10.1016/j.jneuroim.2009.10.015.
6. Torkildsen NG, Lie SA, Nyland HL. Survival and cause of death in multi sclerosis. *Neurol Mult Scaler.* 2008;14:119–99.
7. Celius EG, Smestad C. Change in sex ratio, disease course and age at diagnosis in Oslo MS patients through seven decades. *Acta Neurol Scand.* 2009;120:27–9. doi:10.1111/j.1600-0404.2009.01208.x.
8. Charo IF, Ransohoff RM. The Many Roles of Chemokines and Chemokine Receptors in Inflammation. *N Engl J Med.* 2006;354(6):610–21. doi:10.1056/nejmra052723.
9. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. *Neurology.* 1996;46:907–11.
10. Coles AJ, Cox A, Page E, Jones J, Trip SA, Deans J, et al. The window of therapeutic opportunity in multiple sclerosis. *J Neurol.* 2006;253(1):98–108. doi:10.1007/s00415-005-0934-5.
11. Feinstein A. The clinical neuropsychiatry of multiple sclerosis. 2nd ed. New York, NY: Cambridge University Press; 2007.
12. Marrie RA, Rudick R, Horwitz R, Cutter G, Tyry T, Campagnolo D, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. *Neurology.* 2010;74(13):1041–7. doi:10.1212/wnl.0b013e3181d6b125.
13. Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. *Lancet Neurol.* 2015;14(2):183–93. doi:10.1016/s1474-4422(14)70256-x.
14. Milo R, Miller A. Revised diagnostic criteria of multiple sclerosis. *Autoimmun Rev.* 2014;13(4-5):518–24. doi:10.1016/j.autrev.2014.01.012.
15. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. *Brain.* 1997;120:393–9.
16. Khan F, Turner L, Kilpatrick T. Multidisciplinary rehabilitation for adults with multiple sclerosis. *J Neural Neurosurg Psychiatry.* 2008;79(2):114.

Author biography

Sourabh D Jain, Assistant Professor

Pawandeep Shukla, Associate Professor

Ankit Agrawal, Assistant Professor

Shikha Sharma, Assistant Professor

Cite this article: Jain SD, Shukla P, Agrawal A, Sharma S. A review: Pathophysiology, diagnosis and management of multiple sclerosis. *Int J Pharm Chem Anal* 2021;8(1):16-18.